Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Home Depot
HD
|
+$38M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$36.3M |
| 3 |
ETNB
89bio
ETNB
|
+$36.1M |
| 4 |
Bank of America
BAC
|
+$33.6M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$29.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$92M |
| 2 |
Coca-Cola
KO
|
+$48.2M |
| 3 |
Starbucks
SBUX
|
+$47M |
| 4 |
CRH
CRH
|
+$41.5M |
| 5 |
McDonald's
MCD
|
+$30M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.02% |
| 2 | Technology | 10.47% |
| 3 | Consumer Discretionary | 6.61% |
| 4 | Financials | 5.33% |
| 5 | Communication Services | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Roblox
RBLX
$27.4B
| $13.3M | 0.49% |
+227,710
| New | +$14.3M |
|
52
Merck
MRK
$376B
| $12.9M | 0.48% |
144,100
+91,100
| +172% | +$8.51M |
|
|
CTNM
53
Contineum Therapeutics
CTNM
$647M
| $12M | 0.45% |
1,720,000
| – | – |
|
54
ProKidney
PROK
$336M
| $10.8M | 0.4% |
12,341,266
| – | – |
|
|
MOLN
55
Molecular Partners
MOLN
$165M
| $8.62M | 0.32% |
2,221,494
| – | – |
|
56
Abbott
ABT
$202B
| $7.8M | 0.29% |
58,820
+25,300
| +75% | +$3.22M |
|
57
Monte Rosa Therapeutics
GLUE
$1.22B
| $7.26M | 0.27% |
1,563,798
| – | – |
|
58
Unity
U
$20.7B
| $6.65M | 0.25% |
+339,560
| New | +$7.67M |
|
59
InflaRx
IFRX
$309M
| $6.61M | 0.25% |
6,483,910
+750,000
| +13% | +$1.41M |
|
|
WHWK
60
Whitehawk Therapeutics
WHWK
$270M
| $6.59M | 0.24% |
+3,700,000
| New | +$9.66M |
|
61
Zura Bio
ZURA
$561M
| $6.27M | 0.23% |
4,860,939
| – | – |
|
|
BIOA
62
BioAge Labs
BIOA
$435M
| $5.46M | 0.2% |
1,452,336
| – | – |
|
63
Sutro Biopharma
STRO
$349M
| $4.86M | 0.18% |
746,250
| – | – |
|
64
Sanofi
SNY
$110B
| $4.64M | 0.17% |
83,701
-47,800
| -36% | -$2.59M |
|
|
EXAS
65
DELISTED
Exact Sciences
EXAS
| $4.07M | 0.15% |
94,100
| – | – |
|
66
Disc Medicine
IRON
$3.06B
| $3.97M | 0.15% |
+80,000
| New | +$4.45M |
|
67
Thermo Fisher Scientific
TMO
$233B
| $3.93M | 0.15% |
7,900
| – | – |
|
|
KZR
68
DELISTED
Kezar Life Sciences
KZR
| $3.5M | 0.13% |
716,759
| – | – |
|
69
Cencora
COR
$60.7B
| $3.47M | 0.13% |
12,488
| – | – |
|
70
Danaher
DHR
$154B
| $2.79M | 0.1% |
13,600
| – | – |
|
71
Elanco Animal Health
ELAN
$12B
| $2.66M | 0.1% |
253,600
| – | – |
|
72
Intuitive Surgical
ISRG
$134B
| $2.58M | 0.1% |
5,200
| – | – |
|
73
Alnylam Pharmaceuticals
ALNY
$31.6B
| $2.53M | 0.09% |
+9,370
| New | +$2.41M |
|
|
AARD
74
Aardvark Therapeutics
AARD
$149M
| $2.35M | 0.09% |
+312,500
| New | +$3.51M |
|
75
PepGen
PEPG
$217M
| $2.33M | 0.09% |
1,660,932
+486,611
| +41% | +$1M |
|
Similar funds
Aaron Cowen's Q1 2025 Portfolio in Review
As of Q1 2025, Aaron Cowen held 112 positions worth $2.69B, down 8.2% from $2.93B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Aaron Cowen's Q1 2025 filing shows 16 new, 29 increased, 14 reduced and 12 closed positions. Its largest new stake was Home Depot: 97,571 shares worth $35.8M. The largest sale was Intra-Cellular Therapies Inc., an estimated $92M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.
- Aaron Cowen's largest Q1 2025 buy was Home Depot: 97,571 shares worth $35.8M.
- Aaron Cowen added most to Ultragenyx Pharmaceutical in Q1 2025, an estimated $36.3M increase.
- Aaron Cowen's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $92M.
- Aaron Cowen fully exited Starbucks in Q1 2025, selling an estimated $47M.
- Aaron Cowen's ten largest holdings make up 48% of its $2.69B portfolio in Q1 2025.
- Aaron Cowen opened 16 new positions and closed 12 in Q1 2025.
- Aaron Cowen's portfolio value fell 8.2% quarter-over-quarter to $2.69B.
Based on Suvretta Capital Management's 13F filing for Q1 2025, filed 15 May 2025.